Vanda Pharmaceuticals (VNDA)

• Market cap: $266M
• 1 day: -2.59%
• 5 days: -3.01%
• 1 month: 13.32%
• 3 months: -8.33%
• 6 months: -2.17%
• Year to date: -6.43%
• 1 year: -30.62%
• 5 years: -59.44%
• 10 years: -65.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Employees: 368

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

1.32% more ownership

Funds ownership: 74.0% [Q4 2024] → 75.32% (+1.32%) [Q1 2025]

0% more funds holding

Funds holding: 146 [Q4 2024] → 146 (+0) [Q1 2025]

2% less capital invested

Capital invested by funds: $207M [Q4 2024] → $202M (-$4.98M) [Q1 2025]

17% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 54

77% less call options, than puts

Call options by funds: $748K | Put options by funds: $3.23M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13 188% upside
• Avg. target: $16.50 266% upside
• High target: $20 343% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Olivia Brayer	188% upside $13	Overweight Assumed	14 May 2025
HC Wainwright & Co. Raghuram Selvaraju	343% upside $20	Buy Reiterated	7 May 2025